Riskpilot← Back to searchSign inGet full accessCircius Pharma AB
ABActiveOrg 5592313927Södra Långebergsgatan 34-36Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201913 employees
Revenue 2024
SEK 112,6M
-22% vs 2023
EBITDA margin
0.2%
-99% vs 2023
Equity ratio
83.7%
Financial strength
Net profit 2024
SEK 74K
-98% vs 2023
| Revenue | SEK 112,6M | -22% |
| EBITDA | SEK 190K | -99% |
| Net profit | SEK 74K | -98% |
| Total assets | SEK 153,1M | +0% |
| Equity | SEK 128,3M | +0% |
| Employees | 13 | — |
Legal name
Circius Pharma AB
Org number
5592313927
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
12 december 2019
Share capital
SEK 50 000
Employees
13 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva utveckling och marknadsföring av läkemedel och medicintekniska produkter, äga och förvalta värdepapper, samt därmed förenlig verksamhet.
Address
Södra Långebergsgatan 34-36
Email
jan.g.smith@circiuspharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 27 296 | 103 035 | 143 953 | 112 570 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −2 | −5 526 | 4 727 | 14 458 | 190 |
| Depreciation & amort. | −0 | −1 307 | −2 637 | −2 801 | −2 805 |
| EBIT | −2 | −6 833 | 2 090 | 11 657 | −2 615 |
| Net financials | 301 562 | 103 548 | 472 | −3 032 | 2 781 |
| Profit before tax | 77 249 | 96 715 | 2 563 | 6 433 | 166 |
| Tax | −0 | −0 | −0 | −1 826 | −92 |
| Net profit | 77 249 | 96 715 | 2 563 | 4 607 | 74 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 124 299 | 241 944 | 135 823 | 152 702 | 153 147 |
| Equity | 124 299 | 221 013 | 123 576 | 128 183 | 128 258 |
| Long-term debt | 0 | 627 | 0 | 0 | 0 |
| Short-term debt | 0 | 20 304 | 12 247 | 22 218 | 22 589 |
| Total debt | — | 20 931 | 12 247 | 22 218 | 22 589 |
EBITDA margin
0.2%
This company
15.8%
Market median
-99% vs market
20202024
Equity ratio
83.7%
This company
38.2%
Market median
+119% vs market
20202024
Return on equity
0.1%
This company
18.4%
Market median
-99% vs market
20202024
Net profit margin
0.1%
This company
8.1%
Market median
-99% vs market
20202024
Asset turnover
0.74×
This company
1.12×
Market median
-34% vs market
20202024
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-12-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JE Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2025 |
JG Chief Executive Officer | Chief Executive Officer | 2025 |
CP Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
NM Chief Auditor | Chief Auditor | 2020 – 2022 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Gobia Enterprises AB
Circius Pharma AB (this company)Circius Pharma ApsCircius Pharma ASCIRCIUS PHARMA APSCIRCIUS PHARMA ASBoard members of Circius Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Erik Gustav Smith | Deputy Chief Executive Officer | 0 companies |
| Jan Gustav Smith | Chief Executive Officer | 0 companies |
| Nils Magnus Götenfelt | Chief Auditor | 0 companies |
| Carl Patrik Resebo | Chief Auditor | 0 companies |